Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079766 · ClinicalTrials.gov registry record · Phase 2
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
A Phase 2 study of Chronic Traumatic Encephalopathy, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT02079766: Completed Phase 2 study of Chronic Traumatic Encephalopathy, sponsored by Avid Radiopharmaceuticals.
NCT02079766 is a Phase 2 study of Chronic Traumatic Encephalopathy that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02079766, a Phase 2 study of Chronic Traumatic Encephalopathy, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
Primary Outcome
Flortaucipir uptake was rated visually by sponsor expert reader as 'No Uptake', 'Mild Uptake', 'Moderate Uptake', or 'Intense Uptake'.
Conditions Studied
Interventions
- DRUG Flortaucipir F18
- DRUG florbetapir F 18
Study Locations (2)
Arizona
- Banner Alzheimer's Institute - Phoenix
Massachusetts
- Boston University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
What the finished NCT02079766 record still lists
NCT02079766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Chronic Traumatic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which Flortaucipir F18 is the first listed.
NCT02079766 reports a single indexed study location in Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02079766 about?
NCT02079766 is a clinical study titled "18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy". This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
What is the current status of trial NCT02079766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2014-06. Estimated completion is 2015-10.
What conditions does trial NCT02079766 study?
This clinical trial studies the following conditions: Chronic Traumatic Encephalopathy.
What interventions are being tested in trial NCT02079766?
The interventions under investigation include: Flortaucipir F18 (DRUG), florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT02079766?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02079766 being conducted?
This trial has 2 study locations across Arizona, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Traumatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02079766's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia